Noetik develops frontier AI models trained on extensive multimodal tumor data to predict individual patient responses to cancer treatments. This platform enhances clinical trial enrichment by accurately identifying likely responders for specific therapies. The technology aims to improve drug positioning and accelerate the discovery of novel, human-relevant oncology targets.
Funding
$54M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+9Founders
Product
Problem
Traditional drug discovery methods often fail to capture the complex interactions between tumors and the immune system, hindering the development of effective immunotherapies. Reductionist approaches struggle to account for the emergent complexity of these interactions, leading to limited success in identifying therapeutic targets and designing personalized treatments.
Solution
Noetik leverages artificial intelligence and self-supervised learning to analyze large-scale human multimodal data, enhancing the identification of therapeutic targets for cancer immunotherapies. By creating foundation models for cell and tissue biology, the platform aims to develop precision treatments tailored to individual patients based on their unique tumor-immune interactions. This approach moves beyond traditional methods by incorporating the complexity of tumor-immune dynamics into the drug discovery process, ultimately leading to more effective and personalized cancer treatments. The company focuses on generating and utilizing human multimodal data at an industrial scale, recognizing that patient data provides the most relevant model system for cancer research.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel cancer immunotherapies and personalized treatment strategies.
Features
- AI-driven platform utilizing self-supervised learning for target identification
- Analysis of large-scale human multimodal data to model tumor-immune interactions
- Creation of foundation models for cell and tissue biology to drive therapeutic development
- Focus on precision immunotherapies tailored to individual patient profiles